| Source: |
| Type: |
| Hypoxia-Inducible-Factor 1A (HIF1A gene, HIF1α, HIF-1α protein product) -Dominantly expressed under hypoxia(low oxygen levels) in solid tumor cells -HIF1A induces the expression of vascular endothelial growth factor (VEGF) -High HIF-1α expression is associated with Poor prognosis -Low HIF-1α expression is associated with Better prognosis -Functionally, HIF-1α is reported to regulate glycolysis, whilst HIF-2α regulates genes associated with lipoprotein metabolism. -Cancer cells produce HIF in response to hypoxia in order to generate more VEGF that promote angiogenesis Key mediators of aerobic glycolysis regulated by HIF-1α. -GLUT-1 → regulation of the flux of glucose into cells. -HK2 → catalysis of the first step of glucose metabolism. -PKM2 → regulation of rate-limiting step of glycolysis. -Phosphorylation of PDH complex by PDK → blockage of OXPHOS and promotion of aerobic glycolysis. -LDH (LDHA): Rapid ATP production, conversion of pyruvate to lactate; HIF-1α Inhibitors: -Curcumin: disruption of signaling pathways that stabilize HIF-1α (ie downregulate). -Resveratrol: downregulate HIF-1α protein accumulation under hypoxic conditions. -EGCG: modulation of upstream signaling pathways, leading to decreased HIF-1α activity. -Emodin: reduce HIF-1α expression. (under hypoxia). -Apigenin: inhibit HIF-1α accumulation. |
| 2660- | AL, | Allicin: A review of its important pharmacological activities |
| - | Review, | AD, | NA | - | Review, | Var, | NA | - | Review, | Park, | NA | - | Review, | Stroke, | NA |
| 278- | ALA, | The Multifaceted Role of Alpha-Lipoic Acid in Cancer Prevention, Occurrence, and Treatment |
| - | Review, | NA, | NA |
| 1253- | aLinA, | The Antitumor Effects of α-Linolenic Acid |
| - | Review, | NA, | NA |
| 1159- | And, | Andrographolide, an Anti-Inflammatory Multitarget Drug: All Roads Lead to Cellular Metabolism |
| - | Review, | NA, | NA |
| 958- | Api, | Apigenin suppresses tumor angiogenesis and growth via inhibiting HIF-1α expression in non-small cell lung carcinoma |
| - | in-vitro, | Lung, | NCIH1299 |
| - | in-vitro, | BC, | BT474 |
| 2640- | Api, | Apigenin: A Promising Molecule for Cancer Prevention |
| - | Review, | Var, | NA |
| 2639- | Api, | Plant flavone apigenin: An emerging anticancer agent |
| - | Review, | Var, | NA |
| 2631- | Api, | Apigenin Induces Autophagy and Cell Death by Targeting EZH2 under Hypoxia Conditions in Gastric Cancer Cells |
| - | in-vivo, | GC, | NA | - | in-vitro, | GC, | AGS |
| 2317- | Api, | Apigenin intervenes in liver fibrosis by regulating PKM2-HIF-1α mediated oxidative stress |
| - | in-vivo, | Nor, | NA |
| 2299- | Api, | Flavonoids Targeting HIF-1: Implications on Cancer Metabolism |
| - | Review, | Var, | NA |
| 2318- | Api, | Apigenin as a multifaceted antifibrotic agent: Therapeutic potential across organ systems |
| - | Review, | Nor, | NA |
| 2319- | Api, | Apigenin sensitizes radiotherapy of mouse subcutaneous glioma through attenuations of cell stemness and DNA damage repair by inhibiting NF-κB/HIF-1α-mediated glycolysis |
| - | in-vitro, | GBM, | NA |
| 1537- | Api, | Apigenin as Tumor Suppressor in Cancers: Biotherapeutic Activity, Nanodelivery, and Mechanisms With Emphasis on Pancreatic Cancer |
| - | Review, | PC, | NA |
| 1545- | Api, | The Potential Role of Apigenin in Cancer Prevention and Treatment |
| - | Review, | NA, | NA |
| 1547- | Api, | Apigenin: Molecular Mechanisms and Therapeutic Potential against Cancer Spreading |
| - | Review, | NA, | NA |
| 1548- | Api, | A comprehensive view on the apigenin impact on colorectal cancer: Focusing on cellular and molecular mechanisms |
| - | Review, | Colon, | NA |
| 1553- | Api, | Role of Apigenin in Cancer Prevention via the Induction of Apoptosis and Autophagy |
| - | Review, | NA, | NA |
| 3383- | ART/DHA, | Dihydroartemisinin: A Potential Natural Anticancer Drug |
| - | Review, | Var, | NA |
| 957- | ART/DHA, | Artemisinin inhibits the development of esophageal cancer by targeting HIF-1α to reduce glycolysis levels |
| - | in-vitro, | ESCC, | KYSE150 | - | in-vitro, | ESCC, | KYSE170 |
| 985- | ART/DHA, | Artemisinin suppresses aerobic glycolysis in thyroid cancer cells by downregulating HIF-1a, which is increased by the XIST/miR-93/HIF-1a pathway |
| - | in-vitro, | Thyroid, | TPC-1 | - | Human, | NA, | NA |
| 556- | ART/DHA, | Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing |
| - | Review, | NA, | NA |
| 2324- | ART/DHA, | Research Progress of Warburg Effect in Hepatocellular Carcinoma |
| - | Review, | Var, | NA |
| 1358- | Ash, | Withaferin A: A Dietary Supplement with Promising Potential as an Anti-Tumor Therapeutic for Cancer Treatment - Pharmacology and Mechanisms |
| - | Review, | Var, | NA |
| 1180- | Ash, | Withaferin A Inhibits Liver Cancer Tumorigenesis by Suppressing Aerobic Glycolysis through the p53/IDH1/HIF-1α Signaling Axis |
| - | in-vitro, | Liver, | HepG2 |
| 3177- | Ash, | Emerging Role of Hypoxia-Inducible Factors (HIFs) in Modulating Autophagy: Perspectives on Cancer Therapy |
| - | Review, | Var, | NA |
| 996- | Ba, | Tam, | Baicalein resensitizes tamoxifen‐resistant breast cancer cells by reducing aerobic glycolysis and reversing mitochondrial dysfunction via inhibition of hypoxia‐inducible factor‐1α |
| 2626- | Ba, | Molecular targets and therapeutic potential of baicalein: a review |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 2620- | Ba, | Natural compounds targeting glycolysis as promising therapeutics for gastric cancer: A review |
| - | Review, | GC, | NA |
| 2617- | Ba, | Potential of baicalein in the prevention and treatment of cancer: A scientometric analyses based review |
| - | Review, | Var, | NA |
| 2615- | Ba, | The Multifaceted Role of Baicalein in Cancer Management through Modulation of Cell Signalling Pathways |
| - | Review, | Var, | NA |
| 2295- | Ba, | 5-FU, | Baicalein reverses hypoxia-induced 5-FU resistance in gastric cancer AGS cells through suppression of glycolysis and the PTEN/Akt/HIF-1α signaling pathway |
| - | in-vitro, | GC, | AGS |
| 2289- | Ba, | Rad, | Baicalein Inhibits the Progression and Promotes Radiosensitivity of Esophageal Squamous Cell Carcinoma by Targeting HIF-1A |
| - | in-vitro, | ESCC, | KYSE150 |
| 2290- | Ba, | Research Progress of Scutellaria baicalensis in the Treatment of Gastrointestinal Cancer |
| - | Review, | GI, | NA |
| 2291- | Ba, | BA, | Baicalein and Baicalin Promote Melanoma Apoptosis and Senescence via Metabolic Inhibition |
| - | in-vitro, | Melanoma, | SK-MEL-28 | - | in-vitro, | Melanoma, | A375 |
| 2293- | Ba, | Baicalein suppresses inflammation and attenuates acute lung injury by inhibiting glycolysis via HIF‑1α signaling |
| - | in-vitro, | Nor, | MH-S | - | in-vivo, | NA, | NA |
| 2298- | Ba, | Flavonoids Targeting HIF-1: Implications on Cancer Metabolism |
| - | Review, | Var, | NA |
| 2297- | Ba, | Significance of flavonoids targeting PI3K/Akt/HIF-1α signaling pathway in therapy-resistant cancer cells – A potential contribution to the predictive, preventive, and personalized medicine |
| - | Review, | Var, | NA |
| 2391- | Ba, | Scutellaria baicalensis and its flavonoids in the treatment of digestive system tumors |
| - | Review, | GC, | NA |
| 2474- | Ba, | Anticancer properties of baicalein: a review |
| - | Review, | Var, | NA | - | in-vitro, | Nor, | BV2 |
| 1392- | BBR, | Based on network pharmacology and experimental validation, berberine can inhibit the progression of gastric cancer by modulating oxidative stress |
| - | in-vitro, | GC, | AGS | - | in-vitro, | GC, | MKN45 |
| 1399- | BBR, | Rad, | Radiotherapy Enhancing and Radioprotective Properties of Berberine: A Systematic Review |
| - | Review, | NA, | NA |
| 956- | BBR, | Berberine inhibits HIF-1alpha expression via enhanced proteolysis |
| - | in-vitro, | Nor, | HUVECs | - | in-vitro, | GC, | SCM1 |
| 2708- | BBR, | Berberine decelerates glucose metabolism via suppression of mTOR‑dependent HIF‑1α protein synthesis in colon cancer cells |
| - | in-vitro, | CRC, | HCT116 |
| 2709- | BBR, | Berberine inhibits the glycolysis and proliferation of hepatocellular carcinoma cells by down-regulating HIF-1α |
| - | in-vitro, | HCC, | HepG2 |
| 2686- | BBR, | Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs |
| - | Review, | Nor, | NA |
| - | Trial, | BC, | NA |
| 2766- | BetA, | Role of natural secondary metabolites as HIF-1 inhibitors in cancer therapy |
| - | Review, | Var, | NA |
| 2729- | BetA, | Betulinic acid in the treatment of tumour diseases: Application and research progress |
| - | Review, | Var, | NA |
| 2738- | BetA, | Betulinic Acid Suppresses Breast Cancer Metastasis by Targeting GRP78-Mediated Glycolysis and ER Stress Apoptotic Pathway |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | BT549 | - | in-vivo, | NA, | NA |
| 2731- | BetA, | Betulinic Acid for Glioblastoma Treatment: Reality, Challenges and Perspectives |
| - | Review, | GBM, | NA | - | Review, | Park, | NA | - | Review, | AD, | NA |
| 3522- | Bor, | The Boron Advantage: The Evolution and Diversification of Boron’s Applications in Medicinal Chemistry |
| - | Review, | Var, | NA |
| 715- | Bor, | Boron-containing phenoxyacetanilide derivatives as hypoxia-inducible factor (HIF)-1alpha inhibitors |
| - | in-vitro, | Pca, | HeLa |
| 1652- | CA, | Caffeic Acid and Diseases—Mechanisms of Action |
| - | Review, | Var, | NA |
| - | in-vitro, | Cerv, | SiHa |
| 1259- | CAP, | Capsaicin inhibits HIF-1α accumulation through suppression of mitochondrial respiration in lung cancer cells |
| - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H23 | - | in-vitro, | Lung, | H2009 |
| 1103- | CBD, | Cannabidiol inhibits invasion and metastasis in colorectal cancer cells by reversing epithelial-mesenchymal transition through the Wnt/β-catenin signaling pathway |
| - | vitro+vivo, | NA, | NA |
| 955- | CEL, | Celecoxib Down-Regulates the Hypoxia-Induced Expression of HIF-1α and VEGF Through the PI3K/AKT Pathway in Retinal Pigment Epithelial Cells |
| - | in-vitro, | RPE, | D407 |
| 954- | CGA, | Chlorogenic acid inhibits hypoxia-induced angiogenesis via down-regulation of the HIF-1α/AKT pathway |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | HUVECs |
| 2802- | CHr, | Chrysin inhibits expression of hypoxia-inducible factor-1alpha through reducing hypoxia-inducible factor-1alpha stability and inhibiting its protein synthesis |
| - | in-vitro, | Pca, | DU145 | - | in-vivo, | Pca, | NA |
| 2785- | CHr, | Emerging cellular and molecular mechanisms underlying anticancer indications of chrysin |
| - | Review, | Var, | NA |
| 2786- | CHr, | Chemopreventive and therapeutic potential of chrysin in cancer: mechanistic perspectives |
| - | Review, | Var, | NA |
| 2788- | CHr, | Chrysin: Sources, beneficial pharmacological activities, and molecular mechanism of action |
| - | Review, | Var, | NA |
| 953- | CHr, | Inhibition of Hypoxia-Inducible Factor-1α and Vascular Endothelial Growth Factor by Chrysin in a Rat Model of Choroidal Neovascularization |
| - | in-vivo, | NA, | NA |
| 952- | Cin, | Cinnamon Extract Reduces VEGF Expression Via Suppressing HIF-1α Gene Expression and Inhibits Tumor Growth in Mice |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | GBM, | U251 | - | in-vivo, | Ovarian, | SKOV3 |
| 1568- | Cin, | Can Cinnamon be the Silver Bullet for Cancer? |
| - | Review, | NA, | NA |
| - | Review, | AD, | NA | - | Review, | Var, | NA |
| 1576- | Citrate, | Targeting citrate as a novel therapeutic strategy in cancer treatment |
| - | Review, | Var, | NA |
| 1585- | Citrate, | Sodium citrate targeting Ca2+/CAMKK2 pathway exhibits anti-tumor activity through inducing apoptosis and ferroptosis in ovarian cancer |
| - | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | Ovarian, | A2780S | - | in-vitro, | Nor, | HEK293 |
| 2315- | Citrate, | Why and how citrate may sensitize malignant tumors to immunotherapy |
| - | Review, | Var, | NA |
| 466- | CUR, | Curcumin circumvent lactate-induced chemoresistance in hepatic cancer cells through modulation of hydroxycarboxylic acid receptor-1 |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Liver, | HuT78 |
| 2304- | CUR, | Curcumin decreases Warburg effect in cancer cells by down-regulating pyruvate kinase M2 via mTOR-HIF1α inhibition |
| - | in-vitro, | Lung, | H1299 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Nor, | HEK293 |
| 2307- | CUR, | Cell-Type Specific Metabolic Response of Cancer Cells to Curcumin |
| - | in-vitro, | Colon, | HT29 | - | in-vitro, | Laryn, | FaDu |
| 2688- | CUR, | Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 1874- | DCA, | Dichloroacetate induces apoptosis of epithelial ovarian cancer cells through a mechanism involving modulation of oxidative stress |
| - | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | Ovarian, | MDAH-2774 |
| 1866- | DCA, | MET, | BTZ, | Targeting metabolic pathways alleviates bortezomib-induced neuropathic pain without compromising anticancer efficacy in a sex-specific manner |
| - | in-vivo, | NA, | NA |
| 1444- | Deg, | Deguelin promotes apoptosis and inhibits angiogenesis of gastric cancer |
| - | in-vitro, | GC, | MKN-28 |
| 1442- | Deg, | Deguelin, a novel anti-tumorigenic agent targeting apoptosis, cell cycle arrest and anti-angiogenesis for cancer chemoprevention |
| - | Review, | Var, | NA |
| 1446- | Deg, | Efficacy and mechanism of action of Deguelin in suppressing metastasis of 4T1 cells |
| - | in-vitro, | BC, | 4T1 |
| 951- | DHA, | Docosahexaenoic Acid Attenuates Breast Cancer Cell Metabolism and the Warburg Phenotype by Targeting Bioenergetic Function |
| - | in-vitro, | BC, | BT474 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | MCF10 |
| 1844- | dietFMD, | Unlocking the Potential: Caloric Restriction, Caloric Restriction Mimetics, and Their Impact on Cancer Prevention and Treatment |
| - | Review, | NA, | NA |
| 1621- | EA, | The multifaceted mechanisms of ellagic acid in the treatment of tumors: State-of-the-art |
| - | Review, | Var, | NA |
| 1613- | EA, | Ellagitannins in Cancer Chemoprevention and Therapy |
| - | Review, | Var, | NA |
| 1605- | EA, | Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence |
| - | Review, | Var, | NA |
| 1056- | EGCG, | EGCG, a major green tea catechin suppresses breast tumor angiogenesis and growth via inhibiting the activation of HIF-1α and NFκB, and VEGF expression |
| - | vitro+vivo, | BC, | E0771 |
| 20- | EGCG, | Potential Therapeutic Targets of Epigallocatechin Gallate (EGCG), the Most Abundant Catechin in Green Tea, and Its Role in the Therapy of Various Types of Cancer |
| - | in-vivo, | Liver, | NA | - | in-vivo, | Tong, | NA |
| 692- | EGCG, | EGCG: The antioxidant powerhouse in lung cancer management and chemotherapy enhancement |
| - | Review, | NA, | NA |
| 681- | EGCG, | Suppressing glucose metabolism with epigallocatechin-3-gallate (EGCG) reduces breast cancer cell growth in preclinical models |
| - | vitro+vivo, | BC, | NA |
| 670- | EGCG, | Epigallocatechin-3-gallate and its nanoformulation in cervical cancer therapy: the role of genes, MicroRNA and DNA methylation patterns |
| - | Review, | NA, | NA |
| 668- | EGCG, | The Potential Role of Epigallocatechin-3-Gallate (EGCG) in Breast Cancer Treatment |
| - | Review, | BC, | MCF-7 | - | Review, | BC, | MDA-MB-231 |
| 1516- | EGCG, | Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential |
| - | Review, | NA, | NA |
| 3201- | EGCG, | Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential |
| - | Review, | NA, | NA |
| 3238- | EGCG, | Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications |
| - | Review, | Var, | NA |
| 2302- | EGCG, | Flavonoids Targeting HIF-1: Implications on Cancer Metabolism |
| - | Review, | Var, | NA |
| 2422- | EMD, | Anti-Cancer Effects of Emodin on HepG2 Cells as Revealed by 1H NMR Based Metabolic Profiling |
| - | in-vitro, | HCC, | HepG2 |
| 948- | F, | Low Molecular Weight Fucoidan Inhibits Tumor Angiogenesis through Downregulation of HIF-1/VEGF Signaling under Hypoxia |
| - | vitro+vivo, | Bladder, | T24 | - | in-vitro, | Nor, | HUVECs |
| 2498- | Fenb, | Unexpected Antitumorigenic Effect of Fenbendazole when Combined with Supplementary Vitamins |
| - | in-vivo, | lymphoma, | NA |
| 949- | FIS, | ATAGJ, | Cisplatin, | Ai-Tong-An-Gao-Ji and Fisetin Inhibit Tumor Cell Growth in Rat CIBP Models by Inhibiting the AKT/HIF-1α Signaling Pathway |
| - | in-vivo, | BC, | Walker256 | - | in-vitro, | BC, | Walker256 |
| 2313- | Flav, | Flavonoids against the Warburg phenotype—concepts of predictive, preventive and personalised medicine to cut the Gordian knot of cancer cell metabolism |
| - | Review, | Var, | NA |
| 947- | GA, | Gallic acid, a phenolic compound, exerts anti-angiogenic effects via the PTEN/AKT/HIF-1α/VEGF signaling pathway in ovarian cancer cells |
| - | in-vitro, | Ovarian, | OVCAR-3 | - | in-vitro, | Melanoma, | A2780S | - | in-vitro, | Nor, | IOSE364 | - | Human, | NA, | NA |
| 811- | GAR, | Garcinol exhibits anti-proliferative activities by targeting microsomal prostaglandin E synthase-1 in human colon cancer cells |
| - | in-vitro, | CRC, | HT-29 |
| 2998- | GEN, | Cellular and Molecular Mechanisms Modulated by Genistein in Cancer |
| - | Review, | Var, | NA |
| 4505- | GLA, | Gamma linolenic acid suppresses hypoxia-induced proliferation and invasion of non-small cell lung cancer cells by inhibition of HIF1α |
| - | in-vitro, | NSCLC, | Calu-1 |
| 836- | Gra, | Graviola: A Novel Promising Natural-Derived Drug That Inhibits Tumorigenicity and Metastasis of Pancreatic Cancer Cells In Vitro and In Vivo Through Altering Cell Metabolism |
| - | vitro+vivo, | PC, | NA |
| 834- | Gra, | Anticancer Properties of Graviola (Annona muricata): A Comprehensive Mechanistic Review |
| - | Review, | NA, | NA |
| 1232- | Gra, | Graviola: A Systematic Review on Its Anticancer Properties |
| - | Review, | NA, | NA |
| 2438- | Gra, | Emerging therapeutic potential of graviola and its constituents in cancers |
| - | Review, | Var, | NA |
| 2519- | H2, | Hydrogen: an advanced and safest gas option for cancer treatment |
| - | Review, | Var, | NA |
| 2512- | H2, | Hydrogen Attenuates Allergic Inflammation by Reversing Energy Metabolic Pathway Switch |
| - | in-vivo, | asthmatic, | NA |
| 1633- | HCA, | Hydroxycitric Acid Alleviated Lung Ischemia-Reperfusion Injury by Inhibiting Oxidative Stress and Ferroptosis through the Hif-1α Pathway |
| - | in-vivo, | NA, | NA | - | in-vitro, | Nor, | HUVECs |
| 960- | HNK, | Honokiol Inhibits HIF-1α-Mediated Glycolysis to Halt Breast Cancer Growth |
| - | vitro+vivo, | BC, | MCF-7 | - | vitro+vivo, | BC, | MDA-MB-231 |
| 2082- | HNK, | Revealing the role of honokiol in human glioma cells by RNA-seq analysis |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 |
| 2894- | HNK, | Pharmacological features, health benefits and clinical implications of honokiol |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 2892- | HNK, | Honokiol Induces Apoptosis, G1 Arrest, and Autophagy in KRAS Mutant Lung Cancer Cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H460 | - | in-vitro, | Lung, | H385 | - | in-vitro, | Nor, | BEAS-2B |
| 2896- | HNK, | Honokiol inhibits hypoxia-inducible factor-1 pathway |
| - | in-vivo, | Colon, | CT26 |
| 2900- | HNK, | The Role and Therapeutic Perspectives of Sirtuin 3 in Cancer Metabolism Reprogramming, Metastasis, and Chemoresistance |
| - | Review, | Var, | NA |
| 2864- | HNK, | Honokiol: A Review of Its Anticancer Potential and Mechanisms |
| - | Review, | Var, | NA |
| 1166- | IVM, | The importin α/β-specific inhibitor Ivermectin affects HIF-dependent hypoxia response pathways |
| - | in-vitro, | NA, | NA |
| 974- | JG, | Juglone down-regulates the Akt-HIF-1α and VEGF signaling pathways and inhibits angiogenesis in MIA Paca-2 pancreatic cancer in vitro |
| - | in-vitro, | PC, | MIA PaCa-2 |
| 1243- | LA, | Lactobacilli Modulate Hypoxia-Inducible Factor (HIF)-1 Regulatory Pathway in Triple Negative Breast Cancer Cell Line |
| - | in-vitro, | BC, | MDA-MB-231 |
| 2906- | LT, | Luteolin, a flavonoid with potentials for cancer prevention and therapy |
| - | Review, | Var, | NA |
| 2912- | LT, | Luteolin: a flavonoid with a multifaceted anticancer potential |
| - | Review, | Var, | NA |
| 3276- | Lyco, | Lycopene modulates cellular proliferation, glycolysis and hepatic ultrastructure during hepatocellular carcinoma |
| - | in-vivo, | HCC, | NA |
| 1708- | Lyco, | The Anti-Cancer Activity of Lycopene: A Systematic Review of Human and Animal Studies |
| - | Review, | Var, | NA |
| 4519- | MAG, | Magnolol: A Neolignan from the Magnolia Family for the Prevention and Treatment of Cancer |
| - | Review, | Var, | NA |
| 972- | MAG, | Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells |
| - | vitro+vivo, | Bladder, | T24 |
| 2500- | meben, | Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme |
| - | in-vitro, | GBM, | U87MG | - | in-vivo, | GBM, | NA |
| 1782- | MEL, | Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities |
| - | Review, | Var, | NA |
| 971- | MEL, | Melatonin down-regulates HIF-1 alpha expression through inhibition of protein translation in prostate cancer cells |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP |
| 1066- | MET, | Metformin increases PDH and suppresses HIF-1α under hypoxic conditions and induces cell death in oral squamous cell carcinoma |
| - | in-vitro, | SCC, | NA |
| 970- | MET, | Metformin suppresses HIF-1α expression in cancer-associated fibroblasts to prevent tumor-stromal cross talk in breast cancer |
| 2371- | MET, | The role of pyruvate kinase M2 in anticancer therapeutic treatments |
| - | Review, | Var, | NA |
| 2386- | MET, | Mechanisms of metformin inhibiting cancer invasion and migration |
| - | Review, | Var, | NA |
| 2378- | MET, | Metformin inhibits epithelial-mesenchymal transition of oral squamous cell carcinoma via the mTOR/HIF-1α/PKM2/STAT3 pathway |
| - | in-vitro, | SCC, | CAL27 | - | in-vivo, | NA, | NA |
| 2376- | MET, | Metformin Inhibits Epithelial-to-Mesenchymal Transition of Keloid Fibroblasts via the HIF-1α/PKM2 Signaling Pathway |
| - | in-vitro, | Nor, | NA |
| 2375- | MET, | Metformin inhibits gastric cancer via the inhibition of HIF1α/PKM2 signaling |
| - | in-vitro, | GC, | SGC-7901 |
| 2487- | metroC, | Metronomic Chemotherapy: Possible Clinical Application in Advanced Hepatocellular Carcinoma |
| - | Review, | HCC, | NA |
| 2245- | MF, | Quantum based effects of therapeutic nuclear magnetic resonance persistently reduce glycolysis |
| - | in-vitro, | Nor, | NIH-3T3 |
| 1203- | MSM, | Methylsulfonylmethane Suppresses Breast Cancer Growth by Down-Regulating STAT3 and STAT5b Pathways |
| - | vitro+vivo, | BC, | MDA-MB-231 |
| 1270- | NCL, | Rad, | Niclosamide enhances the antitumor effects of radiation by inhibiting the hypoxia-inducible factor-1α/vascular endothelial growth factor signaling pathway in human lung cancer cells |
| - | in-vivo, | Lung, | NA |
| 968- | OA, | Oroxylin A inhibits glycolysis-dependent proliferation of human breast cancer via promoting SIRT3-mediated SOD2 transcription and HIF1α destabilization |
| - | vitro+vivo, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MBT-2 |
| 1813- | Oxy, | Advances in hyperbaric oxygen to promote immunotherapy through modulation of the tumor microenvironment |
| - | Review, | Var, | NA |
| 2396- | PACs, | PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma |
| - | in-vitro, | HCC, | HCCLM3 | - | in-vitro, | HCC, | SMMC-7721 cell | - | in-vitro, | HCC, | Bel-7402 | - | in-vitro, | HCC, | HUH7 | - | in-vitro, | HCC, | HepG2 | - | in-vitro, | Nor, | L02 |
| 959- | PACs, | Grape seed extract inhibits VEGF expression via reducing HIF-1α protein expression |
| - | in-vitro, | GBM, | U251 | - | in-vitro, | BC, | MDA-MB-231 |
| 2380- | PBG, | Potential Strategies for Overcoming Drug Resistance Pathways Using Propolis and Its Polyphenolic/Flavonoid Compounds in Combination with Chemotherapy and Radiotherapy |
| - | Review, | Var, | NA |
| 1666- | PBG, | Molecular and Cellular Mechanisms of Propolis and Its Polyphenolic Compounds against Cancer |
| - | Review, | Var, | NA |
| 1668- | PBG, | Propolis: A Detailed Insight of Its Anticancer Molecular Mechanisms |
| - | Review, | Var, | NA |
| 1662- | PBG, | The immunomodulatory and anticancer properties of propolis |
| - | Review, | Var, | NA |
| 3259- | PBG, | Propolis and its therapeutic effects on renal diseases: A review |
| - | Review, | Nor, | NA |
| 2953- | PL, | Piperlongumine Acts as an Immunosuppressant by Exerting Prooxidative Effects in Human T Cells Resulting in Diminished TH17 but Enhanced Treg Differentiation |
| - | in-vitro, | Nor, | NA |
| 2999- | PL, | Piperlongumine alleviates corneal allograft rejection via suppressing angiogenesis and inflammation |
| - | in-vivo, | Nor, | HUVECs |
| 2300- | QC, | Flavonoids Targeting HIF-1: Implications on Cancer Metabolism |
| - | Review, | Var, | NA |
| 2303- | QC, | doxoR, | Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1α in tumor and normal cells |
| - | in-vitro, | BC, | 4T1 | - | in-vivo, | NA, | NA |
| 3353- | QC, | Quercetin triggers cell apoptosis-associated ROS-mediated cell death and induces S and G2/M-phase cell cycle arrest in KON oral cancer cells |
| - | in-vitro, | Oral, | KON | - | in-vitro, | Nor, | MRC-5 |
| 3368- | QC, | The potential anti-cancer effects of quercetin on blood, prostate and lung cancers: An update |
| - | Review, | Var, | NA |
| 910- | QC, | The Anti-Cancer Effect of Quercetin: Molecular Implications in Cancer Metabolism |
| 967- | RES, | Resveratrol binds and inhibits transcription factor HIF-1α in pancreatic cancer |
| - | Analysis, | PC, | NA |
| 2332- | RES, | Resveratrol’s Anti-Cancer Effects through the Modulation of Tumor Glucose Metabolism |
| - | Review, | Var, | NA |
| 2471- | RES, | Resveratrol Regulates Glucose and Lipid Metabolism in Diabetic Rats by Inhibition of PDK1/AKT Phosphorylation and HIF-1α Expression |
| - | in-vivo, | Diabetic, | NA |
| 3080- | RES, | Resveratrol: A miraculous natural compound for diseases treatment |
| - | Review, | Var, | NA |
| 3071- | RES, | Resveratrol and Its Anticancer Effects |
| - | Review, | Var, | NA |
| 3076- | RES, | Resveratrol for targeting the tumor microenvironment and its interactions with cancer cells |
| - | Review, | Var, | NA |
| 3064- | RES, | Resveratrol Suppresses Cancer Cell Glucose Uptake by Targeting Reactive Oxygen Species–Mediated Hypoxia-Inducible Factor-1α Activation |
| - | in-vitro, | CRC, | HT-29 | - | in-vitro, | BC, | T47D | - | in-vitro, | Lung, | LLC1 |
| 3055- | RES, | Resveratrol and Tumor Microenvironment: Mechanistic Basis and Therapeutic Targets |
| - | Review, | Var, | NA |
| 3082- | RES, | Resveratrol Ameliorates the Malignant Progression of Pancreatic Cancer by Inhibiting Hypoxia-induced Pancreatic Stellate Cell Activation |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vivo, | NA, | NA |
| 3092- | RES, | Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action |
| - | Review, | BC, | MDA-MB-231 | - | Review, | BC, | MCF-7 |
| 3089- | RES, | The Role of Resveratrol in Cancer Therapy |
| - | Review, | Var, | NA |
| 3081- | RES, | Resveratrol and p53: How are they involved in CRC plasticity and apoptosis? |
| - | Review, | CRC, | NA |
| 2687- | RES, | Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs |
| - | Review, | NA, | NA | - | Review, | AD, | NA |
| 1748- | RosA, | The Role of Rosmarinic Acid in Cancer Prevention and Therapy: Mechanisms of Antioxidant and Anticancer Activity |
| - | Review, | Var, | NA |
| 3022- | RosA, | Rosmarinic acid against cognitive impairment via RACK1/HIF-1α regulated microglial polarization in sepsis-surviving mice |
| - | in-vitro, | Sepsis, | NA |
| 3001- | RosA, | Therapeutic Potential of Rosmarinic Acid: A Comprehensive Review |
| - | Review, | Var, | NA |
| 3036- | RosA, | Anti-Warburg effect of rosmarinic acid via miR-155 in colorectal carcinoma cells |
| - | in-vitro, | CRC, | HCT8 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | LS174T |
| 966- | RT, | Antioxidant Mechanism of Rutin on Hypoxia-Induced Pulmonary Arterial Cell Proliferation |
| - | vitro+vivo, | Nor, | NA |
| 1210- | SANG, | Sanguinarine combats hypoxia-induced activation of EphB4 and HIF-1α pathways in breast cancer |
| - | in-vitro, | BC, | NA |
| 1134- | SANG, | Sanguinarine inhibits epithelial–mesenchymal transition via targeting HIF-1α/TGF-β feed-forward loop in hepatocellular carcinoma |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | HCC, | Hep3B | - | in-vitro, | HCC, | HUH7 |
| 1688- | Se, | Potential Role of Selenium in the Treatment of Cancer and Viral Infections |
| - | Review, | Var, | NA |
| 1725- | SFN, | Anticancer Activity of Sulforaphane: The Epigenetic Mechanisms and the Nrf2 Signaling Pathway |
| - | Review, | Var, | NA |
| 1732- | SFN, | Sulforaphane, a Dietary Component of Broccoli/Broccoli Sprouts, Inhibits Breast Cancer Stem Cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | SUM159 | - | in-vivo, | NA, | NA |
| 1734- | SFN, | Sulforaphane Inhibits Nonmuscle Invasive Bladder Cancer Cells Proliferation through Suppression of HIF-1α-Mediated Glycolysis in Hypoxia |
| - | in-vitro, | Bladder, | RT112 |
| 1726- | SFN, | Sulforaphane: A Broccoli Bioactive Phytocompound with Cancer Preventive Potential |
| - | Review, | Var, | NA |
| 1484- | SFN, | Sulforaphane’s Multifaceted Potential: From Neuroprotection to Anticancer Action |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 1452- | SFN, | Sulforaphane Suppresses the Nicotine-Induced Expression of the Matrix Metalloproteinase-9 via Inhibiting ROS-Mediated AP-1 and NF-κB Signaling in Human Gastric Cancer Cells |
| - | in-vitro, | GC, | AGS |
| 1434- | SFN, | GEM, | Sulforaphane Potentiates Gemcitabine-Mediated Anti-Cancer Effects against Intrahepatic Cholangiocarcinoma by Inhibiting HDAC Activity |
| - | in-vitro, | CCA, | HuCCT1 | - | in-vitro, | CCA, | HuH28 | - | in-vivo, | NA, | NA |
| 1508- | SFN, | Nrf2 targeting by sulforaphane: A potential therapy for cancer treatment |
| - | Review, | Var, | NA |
| 1509- | SFN, | Combination therapy in combating cancer |
| - | Review, | NA, | NA |
| 2556- | SFN, | The role of Sulforaphane in cancer chemoprevention and health benefits: a mini-review |
| - | Review, | Var, | NA |
| 2448- | SFN, | Sulforaphane and bladder cancer: a potential novel antitumor compound |
| - | Review, | Bladder, | NA |
| 2446- | SFN, | CAP, | The Molecular Effects of Sulforaphane and Capsaicin on Metabolism upon Androgen and Tip60 Activation of Androgen Receptor |
| - | in-vitro, | Pca, | LNCaP |
| 2406- | SFN, | Sulforaphane and Its Protective Role in Prostate Cancer: A Mechanistic Approach |
| - | Review, | Pca, | NA |
| 963- | SFN, | Sulforaphane inhibits hypoxia-induced HIF-1α and VEGF expression and migration of human colon cancer cells |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | GC, | AGS |
| 3301- | SIL, | Critical review of therapeutic potential of silymarin in cancer: A bioactive polyphenolic flavonoid |
| - | Review, | Var, | NA |
| 3282- | SIL, | Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions |
| - | Review, | NA, | NA |
| 3288- | SIL, | Silymarin in cancer therapy: Mechanisms of action, protective roles in chemotherapy-induced toxicity, and nanoformulations |
| - | Review, | Var, | NA |
| 3290- | SIL, | A review of therapeutic potentials of milk thistle (Silybum marianum L.) and its main constituent, silymarin, on cancer, and their related patents |
| - | Analysis, | Var, | NA |
| 3289- | SIL, | Silymarin: a promising modulator of apoptosis and survival signaling in cancer |
| - | Review, | Var, | NA |
| 3329- | SIL, | Silymarin regulates the HIF-1 and iNOS expression in the brain and Gills of the hypoxic-reoxygenated rainbow trout (Oncorhynchus mykis) |
| - | in-vivo, | Nor, | NA |
| 3328- | SIL, | Modulatory effect of silymarin on inflammatory mediators in experimentally induced benign prostatic hyperplasia: emphasis on PTEN, HIF-1α, and NF-κB |
| - | in-vivo, | BPH, | NA |
| 3327- | SIL, | Effects of silymarin on HIF‑1α and MDR1 expression in HepG‑2 cells under hypoxia |
| - | in-vitro, | Liver, | HepG2 |
| 3326- | SIL, | Silymarin suppresses proliferation of human hepatocellular carcinoma cells under hypoxia through downregulation of the HIF-1α/VEGF pathway |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Liver, | Hep3B |
| 3325- | SIL, | Modulatory effect of silymarin on pulmonary vascular dysfunction through HIF-1α-iNOS following rat lung ischemia-reperfusion injury |
| - | in-vivo, | Nor, | NA |
| 1001- | SIL, | Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolism |
| - | in-vitro, | NA, | NA |
| 964- | SIL, | Silibinin inhibits hypoxia-induced HIF-1α-mediated signaling, angiogenesis and lipogenesis in prostate cancer cells: In vitro evidence and in vivo functional imaging and metabolomics |
| - | vitro+vivo, | Pca, | LNCaP | - | in-vitro, | Pca, | 22Rv1 |
| 2370- | SK, | The role of pyruvate kinase M2 in anticancer therapeutic treatments |
| - | Review, | Var, | NA |
| 3041- | SK, | Promising Nanomedicines of Shikonin for Cancer Therapy |
| - | Review, | Var, | NA |
| 3051- | SK, | Resveratrol mediates its anti-cancer effects by Nrf2 signaling pathway activation |
| - | Review, | Var, | NA |
| 965- | SK, | Shikonin suppresses proliferation and induces cell cycle arrest through the inhibition of hypoxia-inducible factor-1α signaling |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | SW-620 |
| 2197- | SK, | Shikonin derivatives for cancer prevention and therapy |
| - | Review, | Var, | NA |
| 2194- | SK, | Efficacy of Shikonin against Esophageal Cancer Cells and its possible mechanisms in vitro and in vivo |
| - | in-vitro, | ESCC, | Eca109 | - | in-vitro, | ESCC, | EC9706 | - | in-vivo, | NA, | NA |
| 2193- | SK, | Shikonin Suppresses Lymphangiogenesis via NF-κB/HIF-1α Axis Inhibition |
| - | in-vitro, | Nor, | HMVEC-dLy |
| 1192- | SM, | Abietane diterpenes from Salvia miltiorrhiza inhibit the activation of hypoxia-inducible factor-1 |
| - | in-vitro, | GC, | AGS | - | in-vitro, | Liver, | HepG3 |
| 366- | SNP, | Silver nanoparticles inhibit the function of hypoxia-inducible factor-1 and target genes: insight into the cytotoxicity and antiangiogenesis |
| - | in-vitro, | BC, | MCF-7 |
| 4561- | SNP, | VitC, | Cellular Effects Nanosilver on Cancer and Non-cancer Cells: Potential Environmental and Human Health Impacts |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Nor, | HEK293 |
| 962- | TQ, | Thymoquinone affects hypoxia-inducible factor-1α expression in pancreatic cancer cells via HSP90 and PI3K/AKT/mTOR pathways |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | Nor, | hTERT-HPNE | - | in-vitro, | PC, | AsPC-1 | - | in-vitro, | PC, | Bxpc-3 |
| 2125- | TQ, | Thymoquinone Selectively Kills Hypoxic Renal Cancer Cells by Suppressing HIF-1α-Mediated Glycolysis |
| - | in-vitro, | RCC, | RCC4 | - | in-vitro, | RCC, | Caki-1 |
| 3431- | TQ, | PI3K-AKT Pathway Modulation by Thymoquinone Limits Tumor Growth and Glycolytic Metabolism in Colorectal Cancer |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | SW48 |
| 3115- | VitC, | The NF-κB Transcriptional Network Is a High-Dose Vitamin C-Targetable Vulnerability in Breast Cancer |
| - | in-vitro, | BC, | NA |
| 3114- | VitC, | Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression |
| - | in-vitro, | AML, | NA |
| 3107- | VitC, | Repurposing Vitamin C for Cancer Treatment: Focus on Targeting the Tumor Microenvironment |
| - | Review, | Var, | NA |
| 3146- | VitC, | Vitamin C protects against hypoxia, inflammation, and ER stress in primary human preadipocytes and adipocytes |
| - | in-vivo, | Nor, | NA |
| 632- | VitC, | High-Dose Vitamin C: Preclinical Evidence for Tailoring Treatment in Cancer Patients |
| - | Review, | NA, | NA |
| 1067- | VitC, | Vitamin C activates pyruvate dehydrogenase (PDH) targeting the mitochondrial tricarboxylic acid (TCA) cycle in hypoxic KRAS mutant colon cancer |
| - | in-vivo, | CRC, | NA |
| 1219- | VitC, | Ascorbic acid and ascorbate-2-phosphate decrease HIF activity and malignant properties of human melanoma cells |
| - | in-vitro, | Melanoma, | NA |
| 1211- | VitK2, | Mechanisms of PKC-Mediated Enhancement of HIF-1α Activity and its Inhibition by Vitamin K2 in Hepatocellular Carcinoma Cells |
| - | in-vitro, | HCC, | HUH7 |
| 2621- | Wog, | Natural compounds targeting glycolysis as promising therapeutics for gastric cancer: A review |
| - | Review, | Var, | NA |
| 2301- | Wog, | Flavonoids Targeting HIF-1: Implications on Cancer Metabolism |
| - | Review, | Var, | NA |
| 961- | Z, | Zinc Downregulates HIF-1α and Inhibits Its Activity in Tumor Cells In Vitro and In Vivo |
| - | in-vitro, | RCC, | RCC4 | - | vitro+vivo, | GBM, | U373MG | - | in-vitro, | Nor, | HUVECs |
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:143 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid